[HTML][HTML] Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer
Novel effective treatment is direly needed for patients with pancreatic ductal
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer.
A Bulle, KH Lim - Signal Transduction and Targeted Therapy, 2020 - europepmc.org
Novel effective treatment is direly needed for patients with pancreatic ductal
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
[HTML][HTML] Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer
A Bulle, KH Lim - Signal Transduction and Targeted Therapy, 2020 - ncbi.nlm.nih.gov
Novel effective treatment is direly needed for patients with pancreatic ductal
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
Beyond just a tight fortress: Contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer
A Bulle, KH Lim - 2020 - digitalcommons.wustl.edu
BACKGROUND The aggressive nature of pancreatic ductal adenocarcinoma (PDAC) is
driven intrinsically by powerful genetic mutations and extrinsically by a highly fibro …
driven intrinsically by powerful genetic mutations and extrinsically by a highly fibro …
Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer.
A Bulle, KH Lim - Signal Transduction & Targeted Therapy, 2020 - search.ebscohost.com
Novel effective treatment is direly needed for patients with pancreatic ductal
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer
B Ashenafi, L Kian-Huat - Signal Transduction and Targeted …, 2020 - search.proquest.com
Novel effective treatment is direly needed for patients with pancreatic ductal
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer
A Bulle, KH Lim - Signal transduction and targeted …, 2020 - pubmed.ncbi.nlm.nih.gov
Novel effective treatment is direly needed for patients with pancreatic ductal
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer
A Bulle, KH Lim - Signal Transduction and Targeted Therapy, 2020 - profiles.wustl.edu
Novel effective treatment is direly needed for patients with pancreatic ductal
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …
Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer
A Bulle, KH Lim - Signal Transduction and Targeted Therapy, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Novel effective treatment is direly needed for
patients with pancreatic ductal adenocarcinoma (PDAC). Therapeutics that target the driver …
patients with pancreatic ductal adenocarcinoma (PDAC). Therapeutics that target the driver …